Literature DB >> 16423999

Thymosin beta4 is a determinant of the transformed phenotype and invasiveness of S-adenosylmethionine decarboxylase-transfected fibroblasts.

Pirjo Nummela1, Miao Yin, Mari Kielosto, Virna Leaner, Michael J Birrer, Erkki Hölttä.   

Abstract

S-adenosylmethionine decarboxylase (AdoMetDC) is a key enzyme in the synthesis of polyamines essential for cell growth and proliferation. Its overexpression induces the transformation of murine fibroblasts in both sense and antisense orientations, yielding highly invasive tumors in nude mice. These cell lines hence provide a good model to study cell invasion. Here, the gene expression profiles of these cells were compared with their normal counterpart by microarray analyses (Incyte Genomics, Palo Alto, CA, and Affymetrix, Santa Clara, CA). Up-regulation of the actin sequestering molecule thymosin beta4 was the most prominent change in both cell lines. Tetracycline-inducible expression of thymosin beta4 antisense RNA caused a partial reversal of the transformed phenotype. Further, reversal of transformation by dominant-negative mutant of c-Jun (TAM67) caused reduction in thymosin beta4 mRNA. Interestingly, a sponge toxin, latrunculin A, which inhibits the binding of thymosin beta4 to actin, was found to profoundly affect the morphology and proliferation of the AdoMetDC transformants and to block their invasion in three-dimensional Matrigel. Thus, thymosin beta4 is a determinant of AdoMetDC-induced transformed phenotype and invasiveness. Up-regulation of thymosin beta4 was also found in ras-transformed fibroblasts and metastatic human melanoma cells. These data encourage testing latrunculin A-like and other agents interfering with thymosin beta4 for treatment of thymosin beta4-overexpressing tumors with high invasive and metastatic potential.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16423999     DOI: 10.1158/0008-5472.CAN-05-2421

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Thymosin beta4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK.

Authors:  Ping Qiu; Michelle Kurpakus Wheater; Yue Qiu; Gabriel Sosne
Journal:  FASEB J       Date:  2011-02-22       Impact factor: 5.191

2.  Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.

Authors:  Belamy B Cheung; Owen Tan; Jessica Koach; Bing Liu; Michael S Y Shum; Daniel R Carter; Selina Sutton; Sela T Po'uha; Louis Chesler; Michelle Haber; Murray D Norris; Maria Kavallaris; Tao Liu; Geraldine M O'Neill; Glenn M Marshall
Journal:  Mol Oncol       Date:  2015-04-29       Impact factor: 6.603

3.  Protein signatures for survival and recurrence in metastatic melanoma.

Authors:  William M Hardesty; Mark C Kelley; Deming Mi; Robert L Low; Richard M Caprioli
Journal:  J Proteomics       Date:  2011-04-23       Impact factor: 4.044

Review 4.  Targeting the cytoskeleton against metastatic dissemination.

Authors:  Carmen Ruggiero; Enzo Lalli
Journal:  Cancer Metastasis Rev       Date:  2021-01-20       Impact factor: 9.264

5.  Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma.

Authors:  Jo Caers; Dirk Hose; Ine Kuipers; Tomas Jan Bos; Els Van Valckenborgh; Eline Menu; Elke De Bruyne; Hartmut Goldschmidt; Ben Van Camp; Bernard Klein; Karin Vanderkerken
Journal:  Haematologica       Date:  2009-10-14       Impact factor: 9.941

6.  Thymosin Beta 4 is overexpressed in human pancreatic cancer cells and stimulates proinflammatory cytokine secretion and JNK activation.

Authors:  Yuqing Zhang; Louis W Feurino; Qihui Zhai; Hao Wang; William E Fisher; Changyi Chen; Qizhi Yao; Min Li
Journal:  Cancer Biol Ther       Date:  2007-12-13       Impact factor: 4.742

7.  In silico analysis of combinatorial microRNA activity reveals target genes and pathways associated with breast cancer metastasis.

Authors:  Alan A Dombkowski; Zakia Sultana; Douglas B Craig; Hasan Jamil
Journal:  Cancer Inform       Date:  2011-02-17

8.  Recurrent targets of aberrant somatic hypermutation in lymphoma.

Authors:  Alireza Hadj Khodabakhshi; Ryan D Morin; Anthony P Fejes; Andrew J Mungall; Karen L Mungall; Madison Bolger-Munro; Nathalie A Johnson; Joseph M Connors; Randy D Gascoyne; Marco A Marra; Inanc Birol; Steven J M Jones
Journal:  Oncotarget       Date:  2012-11

Review 9.  Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges.

Authors:  Aneta Gandalovičová; Daniel Rosel; Michael Fernandes; Pavel Veselý; Petr Heneberg; Vladimír Čermák; Luboš Petruželka; Sunil Kumar; Victoria Sanz-Moreno; Jan Brábek
Journal:  Trends Cancer       Date:  2017-06

10.  Divergent roles of lysyl oxidase family members in ornithine decarboxylase- and RAS-transformed mouse fibroblasts and human melanoma cells.

Authors:  Mari Kielosto; Johanna Eriksson; Pirjo Nummela; Miao Yin; Erkki Hölttä
Journal:  Oncotarget       Date:  2018-12-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.